Consolidated Statements of Shareholders' Equity - USD ($)	Total	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Beginning balance at Dec. 31, 2012	$ 31,365,000			$ 109,000	$ 279,464,000	$ (125,000)	$ (248,366,000)	$ 283,000
Beginning balance, shares at Dec. 31, 2012			23,000	10,943,000		(5,000)
Options exercised and restricted shares vested	11,000			$ 1,000	11,000
Options exercised and restricted shares vested, shares				27,000
Issuance of common stock in connection with the acquisition of Juniper Pharma Services	7,295,000			$ 11,000	7,284,000
Issuance of common stock in connection with the acquisition of Juniper Pharma Services, shares				1,051,000
Conversion of series E preferred stock				$ 1,000	(157,000)	$ 156,000
Conversion of series E preferred stock, shares			(23,000)	131,000		11,000
Purchase of treasury stock	(31,000)					$ (31,000)
Purchase of treasury stock, shares						(6,000)
Share based compensation expense	$ 476,000				$ 475,000
Share based compensation expense, shares	0	0	0	0	0	0	0	0
Dividends on preferred stock	$ (28,000)				$ (28,000)
Reverse stock split - cash in lieu	(1,000)				(1,000)
Translation adjustment	1,184,000							$ 1,184,000
Unrealized loss on short term investments	(80,000)							(80,000)
Reclassification adjustment for gains included in net income	(17,000)							(17,000)
Net (loss) income	6,704,000						$ 6,704,000
Ending balance at Dec. 31, 2013	46,878,000			$ 122,000	287,048,000		$ (241,662,000)	$ 1,370,000
Ending balance, shares at Dec. 31, 2013				12,152,000
Options exercised and restricted shares vested	33,000				33,000
Options exercised and restricted shares vested, shares				34,000
Purchase of treasury stock	(8,579,000)					$ (8,579,000)
Purchase of treasury stock, shares						(1,411,000)
Share based compensation expense	$ 607,000				$ 607,000
Share based compensation expense, shares	0	0	0	0	0	0	0	0
Dividends on preferred stock	$ (28,000)				$ (28,000)
Translation adjustment	(1,433,000)							$ (1,433,000)
Net (loss) income	3,390,000						$ 3,390,000
Ending balance at Dec. 31, 2014	40,868,000			$ 122,000	287,660,000	$ (8,579,000)	$ (238,272,000)	$ (63,000)
Ending balance, shares at Dec. 31, 2014				12,186,000		(1,411,000)
Options exercised and restricted shares vested	60,000				82,000	$ (22,000)
Options exercised and restricted shares vested, shares				29,000		(2,000)
Share based compensation expense	$ 1,750,000				$ 1,750,000
Share based compensation expense, shares	0	0	0	0	0	0	0	0
Dividends on preferred stock	$ (28,000)				$ (28,000)
Translation adjustment	(1,099,000)							$ (1,099,000)
Net (loss) income	(2,134,000)						$ (2,134,000)
Ending balance at Dec. 31, 2015	$ 39,417,000			$ 122,000	$ 289,464,000	$ (8,601,000)	$ (240,406,000)	$ (1,162,000)
Ending balance, shares at Dec. 31, 2015				12,215,000		(1,413,000)